China Medical System Holdings Limited (CHSYF)

Overview

Founded in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited (CMS) operates as a reputable investment holding company. It is primarily engaged in the manufacture, sales, marketing, and promotion of pharmaceutical products within the People's Republic of China. CMS has earned recognition for its diverse portfolio of pharmaceutical offerings that cater to a wide range of medical conditions, from acute heart failure and hypertension to mental health disorders and chronic diseases. Through its strategic subsidiary, Treasure Sea Limited, CMS extends its reach in the pharmaceutical industry, ensuring a notable presence and impact. Beyond its core pharmaceutical operations, the company also partakes in agriculture and livestock activities, showcasing its versatility and commitment to meeting diverse market needs.

Products and Services

CMS boasts a comprehensive range of pharmaceutical products aimed at addressing various health concerns and improving patient outcomes. Each product is carefully designed to meet the highest standards of efficacy, safety, and quality, reflecting CMS's dedication to healthcare and medical excellence.

• Plendil: Used for treating hypertension and stable angina pectoris, highlighting CMS’s commitment to cardiovascular health.
• XinHuoSu: A crucial medication for the treatment of acute heart failure, demonstrating CMS's focus on life-saving treatments.
• Deanxit: Addresses mild-to-moderate depression, anxiety, and psychosomatic affections, underscoring the company’s attention to mental health.
• Ursofalk: For the treatment of cholesterol gallstones, cholestatic liver disease, and biliary reflux gastritis, showcasing CMS's expertise in gastroenterology.
• Salofalk: Used in treating Ulcerative Colitis and Crohn's disease, reflecting CMS’s endeavors in chronic inflammatory conditions.
• Bioflor: Targets the treatment of diarrhea, emphasizing CMS’s focus on gastrointestinal health.
• Combizym: A solution for dyspepsia, further signaling the company’s commitment to digestive health treatments.
• Augentropfen Stulln Mono eye drops: Offers relief for senile macula degeneration and asthenopia, showcasing CMS’s investment in ophthalmology.
• Hirudoid: For treating blunt traumata with or without hematomas and superficial phlebitis insofar, underscoring CMS's commitment to supportive care in minor injuries and conditions.
• DanShenTong capsules: Designed for treating a range of infections and inflammatory conditions, highlighting CMS’s dedication to comprehensive healthcare solutions.
• Imdur: A pivotal medication for coronary heart disease, chronic heart failure, and myocardial infarction prevention and management, emphasizing CMS’s focus on critical care for heart conditions.
• Parlodel tablets: Cater to endocrine and neuro system indications, reflecting CMS’s commitment to addressing complex health concerns.
• Elcatonin injection: For osteoporosis treatment, underscoring CMS’s response to the growing need for effective bone health solutions.
• YinlianQinggan granules, Lamisil tablets, and MOVICOL: Address specific health conditions like hepatitis, fungal infections, and constipation, showing CMS's diverse portfolio catering to a wide spectrum of healthcare needs.